Oxytocin and behavior: Evidence for effects in the brain

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 25, Issue 2, 2013, Pages 96-102

  Stevens, Francis L ^a,b,c   Wiesman, Omri ^d   Feldman, Ruth ^d   Hurley, Robin A ^b,e,f,g   Taber, Katherine H ^b,e,f,g  

^a UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Hellenic College   (United States)

^d BAR ILAN UNIVERSITY   (Israel)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g Menninger Dept of Psychiatry and Behavioral Sciences at Baylor College of Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROPEPTIDE; OXYTOCIN;

AMYGDALOID NUCLEUS; ARTICLE; BEHAVIOR; BORDERLINE STATE; BRAIN; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; COGNITION; CORPUS STRIATUM; EMOTION; ENTORHINAL CORTEX; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENERALIZED ANXIETY DISORDER; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS; ORBITAL CORTEX; POSTTRAUMATIC STRESS DISORDER; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA; SUBICULUM; TREATMENT RESISTANT DEPRESSION;

ADMINISTRATION, INTRANASAL; ANIMALS; BEHAVIOR; BRAIN; HUMANS; MAGNETIC RESONANCE IMAGING; OXYTOCIN;

EID: 84883264074     PISSN: 08950172     EISSN: 15457222     Source Type: Journal    
DOI: 10.1176/appi.neuropsych.13030061     Document Type: Article

References (81)

1. Gimpl G, Fahrenholz F: The oxytocin receptor system: structure, function, and regulation. Physiol Rev 2001;81:629-683
2. Insel TR: Oxytocin, a neuropeptide for affiliation: evidence from behavioral, receptor autoradiographic, and comparative studies. Psychoneuroendocrinology 1992; 17:3-35
3. Loup F, Tribollet E, Dubois-Dauphin M, et al: Localization of oxytocin binding sites in the human brainstem and upper spinal cord: an autoradiographic study. Brain Res 1989; 500:223-230
4. Loup F, Tribollet E, Dubois-Dauphin M, et al: Localization of high-affinity binding sites for oxytocin and vasopressin in the human brain: an autoradiographic study. Brain Res 1991; 555:220-232
5. Sofroniew MV: Projections from vasopressin, oxytocin, and neurophysin neurons to neural targets in the rat and human. J Histochem Cytochem 1980; 28:475-478
6. Sofroniew MV, Weindl A, Schrell U, et al: Immunohistochemistry of vasopressin, oxytocin, and neurophysin in the hypothalamus and extrahypothalamic regions of the human and primate brain. Acta Histochem Suppl 1981; 24:79-95
7. Fliers E, Guldenaar SEF, van de Wal N, et al: Extrahypothalamic vasopressin and oxytocin in the human brain; presence of vasopressin cells in the bed nucleus of the stria terminalis. Brain Res 1986; 375:363-367
8. Riem MM, Bakermans-Kranenburg MJ, Pieper S, et al: Oxytocin modulates amygdala, insula, and inferior frontal gyrus responses to infant crying: a randomized, controlled trial. Biol Psychiatry 2011; 70:291-297
9. Riem MM, van IJzendoorn MH, Tops M, et al: No laughing matter: intranasal oxytocin administration changes functional brain connectivity during exposure to infant laughter. Neuropsychopharmacology 2012; 37:1257-1266
10. Kirsch P, Esslinger C, Chen Q, et al: Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci 2005; 25:11489-11493
11. Domes G, Heinrichs M, Gläscher J, et al: Oxytocin attenuates amygdala responses to emotional faces regardless of valence. Biol Psychiatry 2007; 62:1187-1190
12. Domes G, Lischke A, Berger C, et al: Effects of intranasal oxytocin on emotional face-processing in women. Psychoneuroendocrinology 2010; 35:83-93
13. Lischke A, Gamer M, Berger C, et al: Oxytocin increases amygdala reactivity to threatening scenes in females. Psychoneuroendocrinology 2012; 37:1431-1438
14. Modabbernia A, Rezaei F, Salehi B, et al: Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia: an 8-week, randomized, double-blind, placebo-controlled study. CNS Drugs 2013; 27:57-65
15. Young LJ, Flanagan-Cato LM: Editorial comment: oxytocin, vasopressin, and social behavior. Horm Behav 2012; 61:227-229
16. Heinrichs M, von Dawans B, Domes G: Oxytocin, vasopressin, and human social behavior. Front Neuroendocrinol 2009; 30: 548-557
17. Ross HE, Young LJ: Oxytocin and the neural mechanisms regulating social cognition and affiliative behavior. Front Neuroendocrinol 2009; 30:534-547
18. Insel TR: The challenge of translation in social neuroscience: a review of oxytocin, vasopressin, and affiliative behavior. Neuron 2010; 65:768-779
19. Meyer-Lindenberg A, Domes G, Kirsch P, et al: Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat Rev Neurosci 2011; 12:524-538
20. Churchland PS, Winkielman P: Modulating social behavior with oxytocin: how does it work? What does it mean? Horm Behav 2012; 61:392-399
21. De Dreu CK: Oxytocin modulates cooperation within and competition between groups: an integrative review and research agenda. Horm Behav 2012; 61:419-428
22. Feldman R: Oxytocin and social affiliation in humans. Horm Behav 2012; 61:380-391
23. Stoop R: Neuromodulation by oxytocin and vasopressin. Neuron 2012; 76:142-159
24. Yamasue H, Yee JR, Hurlemann R, et al: Integrative approaches utilizing oxytocin to enhance prosocial behavior: from animal and human social behavior to autistic social dysfunction. J Neurosci 2012; 32:14109-14117
25. Striepens N, Kendrick KM, Maier W, et al: Prosocial effects of oxytocin and clinical evidence for its therapeutic potential. Front Neuroendocrinol 2011; 32:426-450
26. Blatt SJ, Zuroff DC, Hawley LL, et al: Predictors of sustained therapeutic change. Psychother Res 2010; 20:37-54
27. Goodson JL: Deconstructing sociality, social evolution, and relevant nonapeptide functions. Psychoneuroendocrinology 2013; 38:465-478
28. Veening JG, de Jong T, Barendregt HP: Oxytocin-messages via the cerebrospinal fluid: behavioral effects; a review. Physiol Behav 2010; 101:193-210
29. Fuxe K, Borroto-Escuela DO, Romero-Fernandez W, et al: On the role of volume transmission and receptor-receptor interactions in social behaviour: focus on central catecholamine and oxytocin neurons. Brain Res 2012; 1476:119-131
30. Feldman R, Gordon I, Zagoory-Sharon O: Maternal and paternal plasma, salivary, and urinary oxytocin and parent-infant synchrony: considering stress and affiliation components of human bonding. Dev Sci 2011; 14:752-761
31. Hoffman ER, Brownley KA, Hamer RM, et al: Plasma, salivary, and urinary oxytocin in anorexia nervosa: a pilot study. Eat Behav 2012; 13:256-259
32. Carter CS, Pournajafi-Nazarloo H, Kramer KM, et al: Oxytocin: behavioral associations and potential as a salivary biomarker. Ann N Y Acad Sci 2007; 1098:312-322
33. Carmichael MS, Humbert R, Dixen J, et al: Plasma oxytocin increases in the human sexual response. J Clin Endocrinol Metab 1987; 64:27-31
34. Skrundz M, Bolten M, Nast I, et al: Plasma oxytocin concentration during pregnancy is associated with development of postpartum depression. Neuropsychopharmacology 2011; 36:1886-1893
35. Strathearn L, Fonagy P, Amico J, et al: Adult attachment predicts maternal brain and oxytocin response to infant cues. Neuropsychopharmacology 2009; 34:2655-2666
36. Strathearn L, Iyengar U, Fonagy P, et al: Maternal oxytocin response during mother-infant interaction: associations with adult temperament. Horm Behav 2012; 61:429-435
37. Weisman O, Zagoory-Sharon O, Feldman R: Oxytocin administration to parent enhances infant physiological and behavioral readiness for social engagement. Biol Psychiatry 2012; 72:982-989
38. Wismer Fries AB, Ziegler TE, Kurian JR, et al: Early experience in humans is associated with changes in neuropeptides critical for regulating social behavior. Proc Natl Acad Sci U S A 2005; 102:17237-17240
39. Andari E, Schneider FC, Mottolese R, et al: Oxytocin's fingerprint in personality traits and regional brain volume. Cereb Cortex 2012; [Epub ahead of print]
40. Grewen KM, Girdler SS, Amico J, et al: Effects of partner support on resting oxytocin, cortisol, norepinephrine, and blood pressure before and after warm partner contact. Psychosom Med 2005; 67:531-538
41. Gonzaga GC, Turner RA, Keltner D, et al: Romantic love and sexual desire in close relationships. Emotion 2006; 6:163-179
42. Schneiderman I, Zagoory-Sharon O, Leckman JF, et al: Oxytocin during the initial stages of romantic attachment: relations to couples' interactive reciprocity. Psychoneuroendocrinology 2012; 37:1277-1285
43. Marazziti D, Dell'Osso B, Baroni S, et al: A relationship between oxytocin and anxiety of romantic attachment. Clin Pract Epidemol Ment Health 2006; 2:28
44. Taylor SE, Saphire-Bernstein S, Seeman TE: Are plasma oxytocin in women and plasma vasopressin in men biomarkers of distressed pair-bond relationships? Psychol Sci 2010; 21:3-7
45. Tabak BA, McCullough ME, Szeto A, et al: Oxytocin indexes relational distress following interpersonal harms in women. Psychoneuroendocrinology 2011; 36:115-122
46. Weisman O, Zagoory-Sharon O, Schneiderman I, et al: Plasma oxytocin distributions in a large cohort of women and men: their gender-specific associations with anxiety. Psychoneuroendocrinology 2013; [E-pub ahead of print]
47. Macdonald K, Feifel D: Oxytocin in schizophrenia: a review of evidence for its therapeutic effects. Acta Neuropsychiatr 2012; 24:130-146
48. Stavropoulos KK, Carver LJ: Research review: social motivation and oxytocin in autism: implications for joint attention development and intervention. J Child Psychol Psychiatry 2013; [E-pub ahead of print]
49. Bartz JA, Zaki J, Bolger N, et al: Social effects of oxytocin in humans: context and person matter. Trends Cogn Sci 2011; 15:301-309
50. Born J, Lange T, Kern W, et al: Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002; 5:514-516
51. Pietrowsky R, Strüben C, Mölle M, et al: Brain potential changes after intranasal vs. intravenous administration of vasopressin: evidence for a direct nose-brain pathway for peptide effects in humans. Biol Psychiatry 1996; 39:332-340
52. Weisman O, Zagoory-Sharon O, Feldman R: Intranasal oxytocin administration is reflected in human saliva. Psychoneuroendocrinology 2012; 37:1582-1586
53. van Ijzendoorn MH, Bhandari R, van der Veen R, et al: Elevated salivary levels of oxytocin persist more than 7 hrs. after intranasal administration. Front Neurosci 2012; 6:174
54. Chang SW, Barter JW, Ebitz RB, et al: Inhaled oxytocin amplifies both vicarious reinforcement and self-reinforcement in rhesus macaques (Macaca mulatta). Proc Natl Acad Sci U S A 2012; 109:959-964
55. Guastella AJ, MacLeod C: A critical review of the influence of oxytocin nasal spray on social cognition in humans: evidence and future directions. Horm Behav 2012; 61:410-418
56. Bos PA, Panksepp J, Bluthé RM, et al: Acute effects of steroid hormones and neuropeptides on human social-emotional behavior: a review of single-administration studies. Front Neuroendocrinol 2012; 33:17-35
57. Zink CF, Meyer-Lindenberg A: Human neuroimaging of oxytocin and vasopressin in social cognition. Horm Behav 2012; 61:400-409
58. Macdonald KS: Sex, receptors, and attachment: a review of individual factors influencing response to oxytocin. Front Neurosci 2012; 6:194
59. Bethlehem RAI, van Honk J, Auyeung B, et al: Oxytocin, brain physiology, and functional connectivity: a review of intranasal oxytocin fMRI studies. Psychoneuroendocrinology 2012; [E-pub ahead of print]
60. Guastella A, Hickie I, McGuinness M, et al: Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research. Psychoneuroendocrinology 2013; E-pub ahead of print
61. Bartels A: Oxytocin and the social brain: beware the complexity. Neuropsychopharmacology 2012; 37:1795-1796
62. Cardoso C, Linnen AM, Joober R, et al: Coping style moderates the effect of intranasal oxytocin on the mood response to interpersonal stress. Exp Clin Psychopharmacol 2012; 20: 84-91
63. Hirosawa T, Kikuchi M, Higashida H, et al: Oxytocin attenuates feelings of hostility depending on emotional context and individuals' characteristics. Sci Rep 2012; 2:384
64. Leknes S, Wessberg J, Ellingsen DM, et al: Oxytocin enhances pupil dilation and sensitivity to "hidden" emotional expressions. Soc Cogn Affect Neurosci 2012; [E-pub ahead of print]
65. Rupp H, James T, Ketterson E, et al: Amygdala response to negative images in postpartum vs nulliparous women and intranasal oxytocin. Soc Cogn Affect Neurosci 2013; [E-pub ahead of print]
66. Sripada CS, Phan KL, Labuschagne I, et al: Oxytocin enhancesresting-state connectivity between amygdala and medial frontal cortex. Int J Neuropsychopharmacol 2013; 16:255-260
67. Riem MM, van Ijzendoorn MH, Tops M, et al: Oxytocin effects on complex brain networks are moderated by experiences of maternal love withdrawal. Eur Neuropsychopharmacol 2013; [E-pub ahead of print]
68. Averbeck BB, Bobin T, Evans S, et al: Emotion recognition and oxytocin in patients with schizophrenia. Psychol Med 2011; 42:1-8
69. Feifel D, Macdonald K, Cobb P, et al: Adjunctive intranasal oxytocin improves verbal memory in people with schizophrenia. Schizophr Res 2012; 139:207-210
70. Fischer-Shofty M, Brüne M, Ebert A, et al: Improving social perception in schizophrenia: the role of oxytocin. Schizophr Res 2013; [E-pub ahead of print]
71. Feifel D, Macdonald K, Nguyen A, et al: Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol Psychiatry 2010; 68:678-680
72. Pedersen CA, Gibson CM, Rau SW, et al: Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia. Schizophr Res 2011; 132:50-53
73. Feifel D: Intranasal oxytocin reduces core symptoms of schizophrenia. Schizophr Res 2012; 136:S69-S70
74. Pedersen C: Oxytocin treatment improves social cognition, PANSS social items scores, and verbal learning in schizophrenia. Schizophr Res 2012; 136:S70
75. Wehring H, Lee MR, McMahon R, et al: Intranasal oxytocin effects on social anxiety and depression in schizophrenia: results from a double-blind, placebo-controlled trial. Schizophr Res 2012; 136:S360
76. Lee MR, Wehring HJ, McMahon RP, et al: Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized, double-blind, placebo controlled pilot study. Schizophr Res 2013; 145:110-115
77. Mithoefer MC, Wagner MT, Mithoefer AT, et al: The safety and efficacy of 1/-3, 4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized, controlled pilot study. J Psychopharmacol 2011; 25:439-452
78. Mithoefer M, Wagner M, Mithoefer A, et al: Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3, 4-methylenedioxymethamphetamine: a prospective, long-term follow-up study. J Psychopharmacol 2013; 27:28-39
79. Oehen P, Traber R, Widmer V, et al: A randomized, controlled pilot study ofMDMA(63, 4-methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic posttraumatic stress disorder (PTSD). J Psychopharmacol 2013; 27:40-52
80. Macdonald K, Macdonald TM: The peptide that binds: a systematic review of oxytocin and its prosocial effects in humans. Harv Rev Psychiatry 2010; 18:1-21
81. Olff M, Langeland W, Witteveen A, et al: A psychobiological rationale for oxytocin in the treatment of posttraumatic stress disorder. CNS Spectr 2010; 15:522-530